Dragonfly Expands its 2019 Collaboration with AbbVie to Develop Novel Therapies for Immune-Mediated Diseases
Shots:
- Dragonfly to receive an upfront & is also eligible to receive future success-based milestones along with royalties
- Under the terms of collaboration, AbbVie to get an exclusive option to license global intellectual property rights for multiple new products
- The collaboration will use Dragonfly's tri-specific NK cell engager therapy (TriNKET) platform to develop additional products for multiple targets for autoimmune and fibrotic diseases. The technology is designed to harness the body's innate immune system to bring treatments options to patients
Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
